株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオシミラー (バイオ後続品) の世界市場 2017年〜2027年:MAb・融合タンパク質・インスリン・エリスロポエチン・G-CSF・インターフェロン・成長ホルモン・受胎能ホルモン

Global Biosimilars and Follow-On Biologics Market 2017-2027: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones

発行 Visiongain Ltd 商品コード 204743
出版日 ページ情報 英文 318 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=153.19円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
バイオシミラー (バイオ後続品) の世界市場 2017年〜2027年:MAb・融合タンパク質・インスリン・エリスロポエチン・G-CSF・インターフェロン・成長ホルモン・受胎能ホルモン Global Biosimilars and Follow-On Biologics Market 2017-2027: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones
出版日: 2017年05月02日 ページ情報: 英文 318 Pages
概要

世界のバイオシミラー市場は、予測期間の前半に38.8%のCAGR (年間複合成長率) 、予測期間の後半に11.3%のCAGRで成長すると予測されています。同市場の規模は2016年に53億1,000万米ドル、2027年に410億7,000万米ドルが推計されています。

当レポートでは、世界のバイオシミラー (バイオ後続品) の市場を取り上げ、バイオシミラーの概要、市場の発展の経緯、市場成長の推進因子・阻害因子の分析、先進国市場および新興国市場における動向、主要薬剤区分別の動向分析および収益予測、SWOT分析、将来の展望などをまとめています。

第1章 レポート概要

第2章 イントロダクション:バイオシミラーとバイオシミラー製剤の開発

  • 生物学的製剤とは?
  • バイオシミラーとは?
  • バイオシミラーの開発の経緯
  • 同質の生物学的製剤とバイオシミラーの違い
  • バイオシミラー市場の主な区分

第3章 世界のバイオシミラー市場の予測

  • 世界のバイオシミラー市場
  • 生物学的製剤市場全体に占めるバイオシミラーのシェア
  • 世界のバイオシミラー市場の予測
  • バイオシミラー市場の成長推進因子
  • バイオシミラー市場の売上成長を阻む要因
  • 世界のバイオシミラー市場における成長推進因子・阻害因子のサマリー
  • 世界のバイオシミラー市場の予測:2次区分別

第4章 主要先進市場におけるバイオシミラーの展望

  • 主要国のバイオシミラー2次市場
  • 国別の2次市場予測
  • 世界市場の地域構成の変化の見通し
  • 米国のバイオシミラー市場展望
  • EUのバイオシミラー市場:歴史・現況

第5章 新興市場におけるバイオシミラーの展望

  • 中国・インドはバイオシミラー収益をリード
  • 主要な新興市場の予測
  • 中国のバイオシミラー市場の展望
  • インドのバイオシミラー市場の展望
  • 韓国の確立されたバイオシミラーガイドライン
  • ロシアのバイオシミラー市場の展望・予測
  • ブラジルのバイオシミラー関連法規制

第6章 モノクローナル抗体 (MAb) のバイオシミラー:区分別の予測とパイプライン

  • 生物学的製剤市場全体におけるMAbの位置付け
  • MAb:数10億ドルの収益をもたらす最大の生物学的製剤市場区分
  • MAbバイオシミラー市場・2次市場の予測
  • MAbバイオシミラー市場の成長推進因子
  • MAbバイオシミラー市場の成長阻害因子
  • バイオシミラー開発の主な標的の予測
  • リツキシマブバイオシミラー
  • インフリキシマブバイオシミラー
  • トラスツズマブバイオシミラー
  • アダリムマブバイオシミラー
  • ベバシズマブバイオシミラー

第7章 融合タンパク質のバイオシミラー:区分別の予測とパイプライン

  • 科学的背景
  • 融合タンパク質の区分
  • 生物学的製剤市場全体における融合タンパク質の位置付け
  • 融合タンパク質バイオシミラー市場の予測
  • エタネルセプトバイオシミラーの予測
  • EYLEA およびアフリベルセプトバイオシミラー
  • オレンシア およびアバタセプトバイオシミラー

第8章 インスリンバイオシミラー:区分別の予測

  • 生物学的製剤市場全体におけるインスリンの位置付け
  • 2030年までに3000万人が糖尿病と診断される見込み
  • 承認済みインスリンバイオシミラー
  • Abasaglar・Basaglar・インスリングラルギンBS:先進市場で初めて承認されるインスリンバイオシミラー
  • EMA:インスリンバイオシミラーガイドラインの最終決定を発表
  • Basaglar:米国で遅れ
  • インスリンバイオシミラー市場・2次市場の予測
  • ヒトインスリンバイオシミラー部門の予測
  • インスリンアナログバイオシミラー部門の予測
  • インスリングラルギンバイオシミラー部門の予測
  • インスリンリスプロバイオシミラー

第9章 エリスロポエチンバイオシミラー:区分別の予測

  • 3種の製品が生物学的EPO薬市場を主導
  • エリスロポエチン刺激剤の安全性上の懸念
  • 経口治療との競合
  • 慢性腎臓病 (CKD) 患者の貧血の治療:EPO薬の主な用途
  • 欧州でのエポエチンバイオシミラーの承認
  • 欧州市場に向けたエポエチンアルファのパイプライン
  • 欧州でのバイオシミラーエポエチンの導入動向
  • 米国に向けたエポエチンアルファのパイプライン
  • 日本でのエポエチンバイオシミラー
  • 韓国でのエポエチンバイオシミラー
  • インド・中国でのエポエチンバイオシミラー
  • 第2世代EPOバイオシミラー
  • ミルセラバイオシミラーの臨床開発:行われていない
  • バイオシミラーEPO市場の予測

第10章 G-CSFバイオシミラー:区分別の予測

  • Amgen:生物学的G-CSFのブランド薬市場をリード
  • Teva:長時間作用性ペグフィルグラスチムを市場投入
  • 世界で承認されている主なフィルグラスチムバイオシミラー
  • バイオシミラーG-CSF市場の予測

第11章 インターフェロンバイオシミラー:区分別の予測

  • インターフェロン:長年の主要な抗ウイルス剤・多発性硬化症治療薬
  • 主なインターフェロンブランド薬
  • 多発性硬化症市場での競合:インターフェロンベータ治療薬との競合
  • インターフェロンアルファ治療薬:すべての経口治療薬と競合に
  • 先進市場で承認されたバイオシミラーはない
  • バイオシミラーインターフェロン市場の予測
  • バイオシミラーインターフェロンアルファ
  • バイオシミラーインターフェロンベータ

第12章 組換えホルモンバイオシミラー:区分別の予測

  • ヒト成長ホルモンの概歴
  • 生物学的成長ホルモン市場:Novo Nordisk・Pfizerが独占的立場
  • 成長ホルモンバイオシミラー
  • 世界で利用可能な複数のバイオシミラー
  • 成長ホルモンバイオシミラー市場の予測
  • 受胎能ホルモン

第13章 バイオシミラー:定性分析・産業動向

  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • 製品パイプライン

第14章 総論

  • 急成長が期待される潜在性の高い市場
  • モノクローナル抗体バイオシミラー:最速成長と期待される部門
  • 様々な要因が需要を刺激
  • バイオシミラーの開発と上市に残される課題

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0188

The global biosimilars and follow-on biologics market is expected to grow at a CAGR of 38.8% in the first half of the forecast period and CAGR of 11.3% in the second half of the forecast period. The market is estimated at $5.31bn in 2016 and $41.07bn in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 318-page report you will receive 128 tables and 68 figures - all unavailable elsewhere.

The 318-page report provides clear detailed insight into the global biosimilars and follow-on biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Biosimilars and Follow-on Biologics Market forecasts from 2017-2027
  • Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2027 for 8 individual therapeutic submarkets:
    • Monoclonal antibodies (mAbs)
    • Fusion proteins
    • Insulin
    • Erythropoietin (EPO)
    • Granulocyte colony-stimulating factor (G-CSF)
    • Interferons
    • Growth hormones
    • Fertility hormones
  • This report also shows revenue to 2027 for 12 individual submarkets within the above segments:
    • Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab
    • Human insulin, insulin analogues, insulin glargine and insulin lispro
    • Interferon alfa and interferon beta
    • Etanercept
  • Our analyses show individual revenue forecasts to 2027 for 12 national markets:
    • US
    • Japan
    • Germany, France, UK, Italy and Spain
    • China, India, South Korea, Russia and Brazil
  • Our study discusses pressures, opportunities and other events affecting the biosimilars industry and market from 2016, including these influences:
    • Strategies for developing biosimilars - needs, demand, challenges and opportunities
    • Guidelines from regulators (FDA, EMA and others)
    • Patent challenges and data exclusivity for biopharmaceuticals
    • Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals
    • Developments in technology and operations for biosimilar drug production.

Visiongain's study is intended for anyone requiring commercial analyses for the biosimilars and follow-on biologics market. You find data, trends and predictions.

Buy our report today Global Biosimilars and Follow-On Biologics Market 2017-2027: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Biosimilars Overview
  • 1.2. Biosimilars Market Segmentation
  • 1.3. Why You Should Read this Report
  • 1.4. How this Report Delivers
  • 1.5. Main Questions Answered by this Report
  • 1.6. Who is this Report for?
  • 1.7. Research and Analysis Methods
  • 1.8. Frequently Asked Questions(FAQ)
  • 1.9. Some Associated Reports
  • 1.10. About Visiongain

2. An Introduction to Biosimilars and Biosimilar Drug Development

  • 2.1. What are Biologics?
    • 2.1.1. Biologics can be Very Effective but also Very Expensive
    • 2.1.2. Brief History of Biological Drug Development
    • 2.1.3. Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
  • 2.2. What are Biosimilars?
  • 2.3. Brief History of Biosimilars
  • 2.4. What are Interchangeable Biological Products and how do They Differ from Biosimilars?
    • 2.4.1. FDA Guidelines on Prescription of Interchangeables vs Biosimilars
    • 2.4.2. Where does the EMA Stand with Regard to Interchangeables?
    • 2.4.3. Where do the EU5 and other European Countries Stand with Regard to Automatic Substitution?
    • 2.4.4. Why Would Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars?
  • 2.5. Main Segments of the Overall Biosimilars Market

3. The Global Biosimilars Market 2016-2027

  • 3.1. The Global Biosimilars Market
  • 3.2. Biosimilars as a Share of the Biologics Market, 2016
    • 3.2.1. Seven of the Top Ten Best-Selling Drugs are Biologics
    • 3.2.2. Outlook for the Overall Biologics Market
  • 3.3. Global Biosimilars Market Forecast, 2016-2027
  • 3.4. What will Drive Growth in the Biosimilars Market?
    • 3.4.1. Biosimilars Can Bring about Savings of Billions - $44bn for the US by 2024 and $33bn for Europe by 2020
    • 3.4.2. Over $67bn Worth of Biologic Patents due to Expire by 2020
    • 3.4.3. US Approves First Biosimilar - Zarxio. Will this Open the Floodgates? Interchangeability Can also Drive Growth
    • 3.4.4. Other Developed and Emerging Markets Will also Provide Opportunities for Growth
    • 3.4.5. Competitive Landscape Emerging for Biosimilars
  • 3.5. What Factors can Restrain Sales Growth in the Biosimilars Market?
    • 3.5.1. Complexity of Biologics Means that Biosimilar Development Faces Many Challenges
    • 3.5.2. Opposition from Originator Companies and Patent Issues
    • 3.5.3. Fragmentation in the Market as Many Companies Chase the Same Targets
    • 3.5.4. The Threat of Biobetters and Next-Generation Biologics
  • 3.6. Summary of the Drivers and Restraints for the Global Biosimilars Market
  • 3.7. Global Biosimilars Market Forecast by Submarket, 2016-2027
    • 3.7.1. Leading Segments in the Biosimilars Market
    • 3.7.2. How Will the Composition of the Market Change Over the Next Ten Years?

4. Outlook for Biosimilars in Leading Developed Markets, 2016-2027

  • 4.1. The Leading National Biosimilar Submarkets
  • 4.2. National Submarket Forecasts 2016-2027
  • 4.3. How will the Regional Composition of the Global Market Change from 2016-2027?
  • 4.4. US Biosimilars Market Outlook 2016-2027
    • 4.4.1. Status of the US Market in 2014-2016
    • 4.4.2. FDA Finalises Three New Guidelines on 351(k) Applications in April 2015
      • 4.4.2.1. The History of the US' Biosimilar Guidelines
    • 4.4.3. FDA Finally Releases Guidance on Biosimilar Naming in August 2015
    • 4.4.4. Individual States Can Pass their Own Biosimilar Substitution Laws
    • 4.4.5. US Biosimilars Market Forecast 2016-2027
  • 4.5. The EU Biosimilar Market: History and Current Status
    • 4.5.1. History of EMA Guidelines and Updates
    • 4.5.2. Biosimilar Uptake in the Europe Varies between Nations
    • 4.5.3. European Biosimilars Market Forecast, 2016-2027
    • 4.5.4. Inflectra and Remsima in Europe - Demonstrates a Path for Other Biosimilar mAbs
    • 4.5.5. German Biosimilar Market Outlook, 2016
      • 4.5.5.1. German Biosimilar Market Forecast, 2016-2027
    • 4.5.6. French Biosimilars Market Outlook, 2016
      • 4.5.6.1. Biosimilar Substitution Passed but Requires Decrees to Come into Effect, Expected Sometime This Year
      • 4.5.6.2. French Biosimilar Market Forecast, 2016-2027
    • 4.5.7. UK Biosimilar Market Outlook, 2016
      • 4.5.7.1. UK Biosimilar Market Forecast, 2016-2027
    • 4.5.8. Italian Biosimilars Market Outlook, 2016
      • 4.5.8.1. Italian Biosimilars Market Forecast, 2016-2027
    • 4.5.9. Spanish Biosimilars Market Outlook, 2016
      • 4.5.9.1. Spanish Biosimilar Market Forecast, 2016-2027
    • 4.5.10. Biosimilar Regulation in Japan and Currently Approved Biosimilars
      • 4.5.10.1. Differences between the European and Japanese Guidelines
      • 4.5.10.2. Currently Approved Biosimilars in Japan
      • 4.5.10.3. Japanese Biosimilar Market Forecast, 2016-2027

5. Outlook for Biosimilars in Emerging Markets, 2016-2027

  • 5.1. China and India Lead Biosimilar Revenues
  • 5.2. Leading Emerging Biosimilar Markets Forecast, 2016-2027
  • 5.3. Chinese Biosimilars Market Outlook, 2016
    • 5.3.1. China Publishes Final Guidelines for Biosimilars
    • 5.3.2. Biosimilars Account for less than Half of Biotech Revenues in China
    • 5.3.3. Chinese Biosimilars Market Forecast, 2016-2027
  • 5.4. Indian Biosimilars Market Outlook, 2016
    • 5.4.1. CDSCO Guidelines Released in 2012
    • 5.4.2. Indian Biosimilars Market Forecast, 2016-2027
  • 5.5. South Korea's Established Biosimilar Guidelines
    • 5.5.1. Currently Approved Biosimilars in South Korea, 2016
    • 5.5.2. South Korean Biosimilars Market Forecast, 2016-2027
  • 5.6. Russian Biosimilars Market Outlook and Forecast, 2016-2027
  • 5.7. Brazilian Biosimilar Regulation
    • 5.7.1. Government Eager to Promote Biosimilar Development, and Two Major Conglomerates, Bionovis and Orygen, are Racing to Produce Biosimilars
    • 5.7.2. Brazilian Biosimilars Market Forecast, 2016-2027

6. Biosimilar Monoclonal Antibodies: Submarket Forecast and Pipeline, 2016-2027

  • 6.1. MAbs as Part of the Overall Biologics Market in 2016
  • 6.2. Monoclonal Antibodies(mAbs): Largest Biologic Submarket, with Individual Drugs Accumulating Multi-Billion Dollar Revenues
  • 6.3. Biosimilar Monoclonal Antibodies Market and Submarkets Forecast, 2016-2027
  • 6.4. Drivers for the Biosimilar Monoclonal Antibodies Market
    • 6.4.1. New Launches of Biosimilar mAbs in Developed and Emerging Markets
    • 6.4.2. Rising Incidence of Cancer will Drive Demand
    • 6.4.3. The Need for Lower Cost Therapies
    • 6.4.4. Partnering to Launch Biosimilar mAbs
  • 6.5. Restraints for the Monoclonal Antibodies Market
    • 6.5.1. Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
      • 6.5.1.1. Hope for Biosimilars when Competing Against Next-Generation Therapies
    • 6.5.2. Challenges in Antibody Development and Manufacturing
    • 6.5.3. Patent Issues, Market Fragmentation and Perception of Biosimilars
  • 6.6. Leading Targets for Biosimilar Development, 2016-2027
  • 6.7. Biosimilar Rituximab
    • 6.7.1. Rituxan: The First Anti-Cancer mAb
    • 6.7.2. Approved Biosimilars and Rituxan Patent Expiry
      • 6.7.2.1. Reditux(Dr. Reddy's Laboratories): First Biosimilar Rituximab
      • 6.7.2.2. MabTas(Intas Pharmaceutical): Another Indian Biosimilar
      • 6.7.2.3. AcellBia(Biocad): The Leading Biosimilar Rituximab
      • 6.7.2.4. Kikuzubam(PROBIOMED) - Faced Challenges
    • 6.7.3. Biosimilar Rituximab Pipeline, 2016-2027
      • 6.7.3.1. Terminated Developments
      • 6.7.3.2. GP2013(Sandoz): One of the Biggest Names in the Biosimilar Industry Throws its Hat into the Ring with Advanced Stage Candidate
      • 6.7.3.3. BI 695500(Boehringer Ingelheim)
      • 6.7.3.4. MabionCD20(Mabion): Focusing on Markets with High Demand
      • 6.7.3.5. CT-P10(Celltrion)
      • 6.7.3.6. PF-05280586(Pfizer)
    • 6.7.4. Biosimilar Rituximab: Revenue Forecast 2016-2027
  • 6.8. Biosimilar Infliximab
    • 6.8.1. Remicade: Second Only to Humira
    • 6.8.2. Approved Biosimilars and Remicade Patent Expiry: Uncertainty in the US after FDA Rejection
      • 6.8.2.1. Inflectra and Remsima(Hospira and Celltrion)
      • 6.8.2.2. Celltrion Speeds Ahead with US FDA Filing, and Inflectra Approved in Australia and Canada
      • 6.8.2.3. Infliximab and BOW015(Epirus Biopharmaceuticals and Ranbaxy Laboratories)
    • 6.8.3. Biosimilar Infliximab Pipeline, 2015-2027
      • 6.8.3.1. SB2(Samsung Bioepis): Has been Filed for EU Approval and Shows Positive Phase 3 Results
      • 6.8.3.2. NI-071(Nichi-Iko): Advanced Stages
      • 6.8.3.3. ABP 710(Amgen) and BX2922(BioXpress Therapeutics)
    • 6.8.4. Biosimilar Infliximab: Revenue Forecast 2016-2027
  • 6.9. Biosimilar Trastuzumab
    • 6.9.1. Herceptin: Another Jewel in Roche's Cancer mAb Portfolio
    • 6.9.2. Approved Biosimilars and Herceptin Patent Expiry
      • 6.9.2.1. Hertraz and CanMab(Mylan and Biocon): The First to Win Approval
      • 6.9.2.2. Herzuma(Celltrion)
    • 6.9.3. Biosimilar Trastuzumab Pipeline, 2015-2027
      • 6.9.3.1. BCD-022(Biocad): Leading Biosimilar Rituximab Developer Tries its Hand at Trastuzumab
      • 6.9.3.2. ABP 980(Amgen and Allergan): Phase 3
      • 6.9.3.3. PF-05280014(Pfizer): Phase 3
      • 6.9.3.4. SB3(Samsung Bioepis) and BX2318(BioXpress Therapeutics)
    • 6.9.4. Biosimilar Trastuzumab: Revenue Forecast 2016-2027
  • 6.10. Biosimilar Adalimumab
    • 6.10.1. Humira - The World's Best-Selling Prescription Drug
    • 6.10.2. Approved Biosimilars and Humira Patent Expiry
      • 6.10.2.1. Exemptia(Zydus Cadila): The First Biosimilar Adalimumab
    • 6.10.3. Biosimilar Adalimumab Pipeline, 2015-2027
      • 6.10.3.1. ABP 501(Amgen and Allergan): Positive Phase 3 Results Released
      • 6.10.3.2. GP2017(Sandoz): Phase 3
      • 6.10.3.3. BI 695501(Boehringer Ingelheim)
      • 6.10.3.4. SB5(Samsung Bioepis): Phase 3 Results
    • 6.10.4. Biosimilar Adalimumab: Revenue Forecast 2016-2027
  • 6.11. Biosimilar Bevacizumab
    • 6.11.1. Avastin: High Revenues and Late Patent Expiry
    • 6.11.2. Biosimilar Bevacizumab Pipeline, 2016-2027
      • 6.11.2.1. BCD-021(Biocad)
      • 6.11.2.2. ABP 215(Amgen and Allergan): Positive Phase 3 Results
      • 6.11.2.3. BI 695502(Boehringer Ingelheim): Phase 3
      • 6.11.2.4. PF-06439535(Pfizer): Phase 3
    • 6.11.3. Biosimilar Bevacizumab: Revenue Forecast, 2016-2027

7. Biosimilar Fusion Proteins: Submarket Forecast and Pipeline, 2016-2027

  • 7.1. Scientific Background
  • 7.2. Differentiating Fusion Proteins
  • 7.3. Fusion Proteins as Part of the Overall Biologics Market
  • 7.4. Biosimilar Fusion Proteins Market Forecast, 2016-2027
  • 7.5. Biosimilar Etanercept, 2016-2027
    • 7.5.1. Enbrel is the Leading Fusion Protein
    • 7.5.2. Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU
    • 7.5.3. Multiple Biosimilars Available in Emerging Markets
      • 7.5.3.1. Brenzys / SB4(Merck and Samsung Bioepis): First Product Approval to Result from Biosimilar Collaboration
      • 7.5.3.2. Yi Sai Pu(Shanghai CP Guojian Pharmaceutical) and Qiangke(Shanghai Celgen Biopharmaceutical)
      • 7.5.3.3. Etacept(Cipla) and Intacept(Intas Pharmaceuticals)
      • 7.5.3.4. Davictrel / HD-203(Hanwha Chemical and Merck KGaA)
    • 7.5.4. Biosimilar Etanercept Pipeline
    • 7.5.5. GP2015(Sandoz)
      • 7.5.5.1. Sandoz Goes in Early: FDA Accepts Application for GP2015, Despite the Fact that Enbrel Patents are not due to Expire any time Soon
    • 7.5.6. SB4(Samsung Bioepis): EMA Accepts Application
      • 7.5.6.1. Samsung Bioepis Releases Positive Phase 3 Data for SB4
    • 7.5.7. CHS-0214(Coherus Biosciences and Baxter)
    • 7.5.8. TuNEX / ENIA11(Mycenax Biotech / TSH Biopharm Corp): Phase 3 in Taiwan
    • 7.5.9. LBEC0101(LG Life Sciences): Phase 3
    • 7.5.10. Biosimilar Etanercept: Revenue Forecast 2016-2027
  • 7.6. Eylea and Biosimilar Aflibercept
  • 7.7. Orencia and Biosimilar Abatacept

8. Biosimilar Insulin Submarket Outlook, 2016-2027

  • 8.1. Insulin as Part of the Biological Drug Sector
  • 8.2. 30 Million People Expected to be Diagnosed with Diabetes by 2030
  • 8.3. Approved Insulin Biosimilars
  • 8.4. Abasaglar / Basaglar / Insulin Glargine BS - The First Insulin Biosimilars to be Approved in Developed Markets
  • 8.5. EMA Releases Finalised Insulin Biosimilars Guideline
  • 8.6. Basaglar Delayed in the US until End of 2016
  • 8.7. Biosimilar Insulin Market and Submarkets Forecast, 2016-2027
  • 8.8. Biosimilar Human Insulin Submarket, 2016-2027
    • 8.8.1. A Submarket Mostly Restricted to Emerging Markets?
    • 8.8.2. Biosimilar Human Insulin in China
    • 8.8.3. Biosimilar Human Insulin in India
      • 8.8.3.1. Wockhardt and Biocon - Given up on their Desire to Target the US and Europe?
    • 8.8.4. Biosimilar Human Insulin in Russia
    • 8.8.5. Biosimilar Human Insulin Submarket Forecast, 2016-2027
  • 8.9. Biosimilar Insulin Analogues Submarket, 2016-2027
    • 8.9.1. Available Biologic Insulin Analogues - Sanofi's Lantus Tops Revenues
    • 8.9.2. Insulin Glargine in the Main Biosimilar Target
      • 8.9.2.1. Limited Development for the Other Targets
    • 8.9.3. Insulin Market Leaders are Developing Ultra-Rapid Acting Insulin Analogues
      • 8.9.3.1. Ultra-Long Acting Insulin also in Development
    • 8.9.4. Mylan Partners with Biocon for Insulin Analogues
    • 8.9.5. Biosimilar Insulin Analogue Revenue Forecast, 2016-2027
  • 8.10. Biosimilar Insulin Glargine
    • 8.10.1. Biosimilars in India and China
    • 8.10.2. Biosimilar Insulin Glargine Pipeline
      • 8.10.2.1. MK-1293(Merck / Samsung Bioepis)
      • 8.10.2.2. Mylan's Insulin Glargine(Mylan and Biocon)
    • 8.10.3. Biosimilar Insulin Glargine: Revenue Forecast, 2016-2027
  • 8.11. Biosimilar Insulin Lispro
    • 8.11.1. One Biosimilar is Currently Available - Prandlin
    • 8.11.2. Much Smaller Pipeline than for Insulin Glargine
    • 8.11.3. Biosimilar Insulin Lispro: Revenue Forecast, 2016-2027

9. Biosimilar Erythropoietins Submarket Outlook, 2016-2027

  • 9.1. Three Products Lead the Biologic EPO Therapy Market
  • 9.2. Safety Concerns for Erythropoietin-Stimulating Agents
  • 9.3. The Challenge from Oral Therapies is Coming
  • 9.4. Treating Anaemia in Patients with CKD - the Leading Use of EPO Therapies
  • 9.5. Biosimilar Epoetin Approvals in Europe
  • 9.6. Epoetin Alfa Pipeline for the European Market
  • 9.7. Trends in Uptake for Biosimilar Epoetins in Europe
  • 9.8. Epoetin Alfa Pipeline for the US - Companies Preparing for Launch
    • 9.8.1. Pfizer's Retacrit Delayed after Response Letter from FDA
    • 9.8.2. Binocrit / HX575 has Completed Trials
  • 9.9. Biosimilar Epoetin in Japan
  • 9.10. Biosimilar Epoetin in South Korea
  • 9.11. Biosimilar Epoetin in India and China
  • 9.12. Second-Generation EPO Biosimilars
  • 9.13. No Mircera Biosimilars in Clinical Development
  • 9.14. Biosimilar EPO Market Forecast, 2016-2027

10. Biosimilar G-CSF Submarket Outlook, 2016-2027

  • 10.1. Amgen Leads the Branded Biologic G-CSF Market
  • 10.2. Teva Launches Long-Acting Pegfilgrastim
  • 10.3. Selected Filgrastim Biosimilars Approved Worldwide
    • 10.3.1. The European G-CSF Biosimilars Market
      • 10.3.1.1. Trends in Biosimilar Uptake Across Europe
    • 10.3.2. Tevagrastim(Teva): The First Biosimilar in Europe, Launched as Granix in the US
    • 10.3.3. Nivestim(Hospira - Pfizer)
    • 10.3.4. Zarzio(Sandoz): The Most Prescribed Biosimilar Therapy in Europe
    • 10.3.5. Zarxio Becomes the First Biosimilar to be Approved in the US, Launched in September
    • 10.3.6. Apotex: FDA has Accepted Applications for both its Biosimilar Filgrastim, and its Biosimilar Pegfilgrastim
    • 10.3.7. Multiple Launches in Japan in Recent Years
    • 10.3.8. Biosimilar Filgrastim and Pegfilgrastim in India
    • 10.3.9. Biosimilars in Russia, China and Other Emerging Markets
  • 10.4. Biosimilar G-CSF Market Forecast, 2016-2027

11. Biosimilar Interferons Submarket Outlook, 2016-2027

  • 11.1. Interferons: Key Antiviral and MS Therapies Since the 1990s
  • 11.2. Leading Interferon Brands
  • 11.3. Competition for the Multiple Sclerosis Market - Challenges for Interferon Beta Therapies
  • 11.4. All-Oral Regimens will Challenge Interferon Alfa Therapy
    • 11.4.1. However Oral Therapies will be Expensive
  • 11.5. There are no Approved Biosimilars in Developed Markets
  • 11.6. Biosimilar Interferon Market Forecast, 2016-2027
  • 11.7. Biosimilar Interferon Alfa
    • 11.7.1. Biosimilar Interferon Alfa - a Common Target in Developing Countries, Leading to Fragmented Markets
    • 11.7.2. Biosimilar Peginterferon Alfa
    • 11.7.3. Hepatitis Treatment Rates are Low
    • 11.7.4. Biosimilar Interferon Alfa Submarket Forecast, 2016-2027
  • 11.8. Biosimilar Interferon Beta
    • 11.8.1. Biosimilars are Well-Established in Emerging Markets
    • 11.8.2. Biosimilar Interferon Beta Pipeline
    • 11.8.3. EMA Guidance
    • 11.8.4. Long-Acting Interferon Beta
    • 11.8.5. Biosimilar Interferon Beta Submarket Forecast, 2016-2027

12. Biosimilar Recombinant Hormones Submarket Outlook, 2016-2027

  • 12.1. Human Growth Hormone: First Extracted in 1958
  • 12.2. Biologic Growth Hormone Market in 2014 - Novo Nordisk and Pfizer Dominate
    • 12.2.1. Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640 Somatropin Candidate
  • 12.3. Biosimilar Growth Hormones
    • 12.3.1. Omnitrope - Well Established in Developed Markets
  • 12.4. Multiple Biosimilars Available Worldwide
    • 12.4.1. Biosimilars Growth Hormones Outside of Asia
    • 12.4.2. Biosimilar Growth Hormones in Asia
    • 12.4.3. Biosimilar Uptake Varies by Region
  • 12.5. Biosimilar Growth Hormones Market Forecast, 2016-2027
  • 12.6. Fertility Hormones
    • 12.6.1. Two Products Lead the Branded Fertility Hormone Market
    • 12.6.2. Long-Acting Follicle Stimulating Hormone(FSH)
    • 12.6.3. Branded Fertility Hormones Market Outlook
    • 12.6.4. Available Biosimilar Fertility Hormones
    • 12.6.5. Biosimilars Approved in Europe
      • 12.6.5.1. Ovaleap(Teva)
      • 12.6.5.2. Befomla(Finox Biotech) Approved in Europe, Undergoing Phase 3 for US
    • 12.6.6. Rising Infertility to Drive Demand to 2027
    • 12.6.7. Biosimilar Fertility Hormones Market Forecast, 2016-2027

13. Biosimilars: Qualitative Analysis and Industry Trends

  • 13.1. SWOT Analysis of the Biosimilars Market
  • 13.2. Biosimilars Market: Strengths
    • 13.2.1. Biosimilars Can Offer Huge Cost Savings
    • 13.2.2. The US has Finally Joined the Global Biosimilars Market
    • 13.2.3. Biosimilars are Already Well-Established in Many National Markets
    • 13.2.4. Outsourcing Offers the Chance for Further Cost Savings
  • 13.3. Biosimilars Market: Weaknesses
    • 13.3.1. Biosimilars are High Cost to Develop and Manufacture
    • 13.3.2. Complexity Means that Development Timelines are Long
    • 13.3.3. Uptake for Biosimilars Varies and is Low in Some Regions
  • 13.4. Biosimilars Market: Opportunities
    • 13.4.1. Blockbuster Biologics Face Patent Expiry
    • 13.4.2. Rising Disease Prevalence
    • 13.4.3. Licensing Agreements for Biosimilars
  • 13.5. Threats
    • 13.5.1. Biobetters and Next-Generation Biologics
    • 13.5.2. Patent Issues and Product Life Cycle Management from Originator Companies
    • 13.5.3. Fragmentation in the Market
    • 13.5.4. Long Market and Data Exclusivity Periods
    • 13.5.5. Biosimilars Require Marketing and Education
  • 13.6. Biosimilar Product Pipeline

14. Conclusions from Visiongain's Research and Analysis

  • 14.1. Rapid Growth Expected for this High-Potential Market
  • 14.2. Biosimilar Monoclonal Antibodies to be the Fastest Growing Segment
  • 14.3. A Range of Factors Will Stimulate Demand
  • 14.4. Challenges Remain in Developing and Successfully Launching Biosimilars
  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1 Sample Table 1
  • Table 1.2 Sample Table 2
  • Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1993
  • Table 3.1 Top Ten Best-Selling Drugs of 2016 (Wihtin the Overall Pharmaceutical Market): Revenues ($bn), Market Shares (%)
  • Table 3.2 Global Biosimilars Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.3 Global Biosimilars Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.4 Patent Status for Leading Biologics within the Overall Biologics Market, 2016
  • Table 3.5 Biosimilars Market Forecast by Submarket (Insulin, EPO, G-CSF, Growth Hormones, mAbs): Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2014-2020
  • Table 3.6 Biosimilars Market Forecast by Submarket (Interferons, Fusion Proteins, Fertility Hormones, Other Biosimilars): Revenue ($bn), AGR (%),CAGR (%), Market Shares (%), 2014-2020
  • Table 3.7 Biosimilars Market Forecast by Submarket (Insulin, EPO, G-CSF, Growth Hormones, mAbs): Revenue ($bn), AGR (%),CAGR (%), Market Shares(%), 2021-2027
  • Table 3.8 Biosimilars Market Forecast by Submarket (Interferons, Fusion Proteins, Fertility Hormones, Other Biosimilars): Revenue ($bn), AGR (%),CAGR (%), Market Shares (%), 2021-2027
  • Table 4.1 Global Biosimilars Market by Region: Revenues ($bn), Market Share (%), 2016
  • Table 4.2 Global Biosimilars Market Forecast Segmented by Nation (China, EU, India, US, South Korea, Japan): Revenue ($bn), AGR (%),CAGR (%),Market Share(%), 2014-2020
  • Table 4.3 Global Biosimilars Market Forecast Segmented by Nation (Russia, Brazil, Other): Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 4.4 Global Biosimilars Market Forecast Segmented by Nation (China, EU, India, US, South Korea, Japan): Revenue ($bn), AGR (%),CAGR (%),Market Share (%), 2021-2027
  • Table 4.5 Global Biosimilars Market Forecast Segmented by Nation (Russia, Brazil, Other): Revenue ($bn), AGR (%), CAGR (%), Market Share(%), 2021-2027
  • Table 4.6 U.S. Biosimilar Approvals To-Date, 2017
  • Table 4.7 US Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 4.8 US Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 4.9 European Biosimilar Approvals: Monoclonal Antibodies and Insulin
  • Table 4.10 European Biosimilar Approvals: G-CSF
  • Table 4.11 European Biosimilar Approvals: EPO
  • Table 4.12 European Biosimilar Approvals: Growth Hormones and Fertility Hormones
  • Table 4.13 European Biosimilars Market Segmented by Leading Nations: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 4.14 European Biosimilars Market Segmented by Leading Nations: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 4.15 German Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 4.16 German Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 4.17 French Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 4.18 French Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 4.19 UK Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 4.20 UK Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 4.21 Italian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 4.22 Italian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 4.23 Spanish Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 4.24 Spanish Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 4.25 Japanese Biosimilar Approvals To-Date, 2016
  • Table 4.26 Japanese Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 4.27 Japanese Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 5.1 Leading Emerging Biosimilar Markets: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 5.2 Leading Emerging Biosimilar Markets: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 5.3 Chinese Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 5.4 Chinese Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 5.5 Indian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 5.6 Indian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 5.7 Currently Approved Biosimilars in South Korea, 2016
  • Table 5.8 South Korean Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 5.9 South Korean Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 5.10 Russian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 5.11 Russian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 5.12 Brazilian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 5.13 Brazilian Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.1 The Best-Selling mAbs of 2016: Revenue ($bn), 2016
  • Table 6.2 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 6.3 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 6.4 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 6.5 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 6.6 Patent Status of Five Leading mAbs, 2016
  • Table 6.7 Types of Next-Generation Antibody Therapy, 2016
  • Table 6.8 Past and Present GP2013 (Sandoz) Clinical Trials, 2016
  • Table 6.9 Ongoing BI 695500 (Boehringer Ingelheim) Clinical Trials, 2016
  • Table 6.10 Ongoing CT-P10 (Celltrion) Clinical Trials, 2016
  • Table 6.11 Past and Present PF-05280586 (Pfizer) Clinical Trials, 2016
  • Table 6.12 Biosimilar Rituximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 6.13 Biosimilar Rituximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 6.14 Biosimilar Infliximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 6.15 Biosimilar Infliximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 6.16 Ongoing PF-05280014 (Pfizer) Clinical Trials, 2016
  • Table 6.17 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 6.18 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 6.19 Recent ABP 501 (Amgen and Allergan) Clinical Trials, 2016
  • Table 6.20 Ongoing BI 695501 (Boehringer Ingelheim) Clinical Trials, 2016
  • Table 6.21 Biosimilar Adalimumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 6.22 Biosimilar Adalimumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 6.23 Recent BCD-021 (Biocad) Clinical Trials, 2016
  • Table 6.24 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 6.25 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 7.1 Biosimilar Fusion Proteins Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 7.2 Biosimilar Fusion Proteins Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 7.3 Amgen's US Patents and Expiry Dates for Enbrel
  • Table 7.4 Ongoing CHS-0214 (Coherus Biosciences and Baxter) Clinical Trials, 2016
  • Table 7.5 Biosimilar Etanercept Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 7.6 Biosimilar Etanercept Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 8.1 Diabetes Prevalence in Leading National Markets, 2012
  • Table 8.2 Selected Insulin Biosimilars which have been Approved and Launched
  • Table 8.3 Biosimilar Insulin Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 8.4 Biosimilar Insulin Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 8.5 Biosimilar Insulin Submarket Forecasts: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 8.6 Biosimilar Insulin Submarket Forecasts: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 8.7 Biosimilar Human Insulin Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 8.8 Biosimilar Human Insulin Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 8.9 Approved Insulin Analogues Marketed Worldwide, 2016
  • Table 8.10 Biosimilar Insulin Analogues Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 8.11 Biosimilar Insulin Analogues Submarket Forecast: Revenue ($bn), AGR (%),CAGR (%), 2021-2027
  • Table 8.12 MK-1293 (Merck / Samsung Bioepis) Recent Clinical Trials, 2016
  • Table 8.13 Insulin Glargine Biosimilar (Mylan and Biocon) Ongoing Clinical Trials, 2016
  • Table 8.14 Biosimilar Insulin Glargine Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 8.15 Biosimilar Insulin Glargine Revenue Forecast: Revenue ($bn), AGR (%),CAGR (%), 2021-2027
  • Table 8.16 Biosimilar Insulin Lispro Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 8.17 Biosimilar Insulin Lispro Revenue Forecast: Revenue ($bn), AGR (%),CAGR (%), 2021-2027
  • Table 9.1 Ongoing ASP1517 (Astellas Pharma) Clinical Trials, 2016
  • Table 9.2 Binocrit / HX575 (Novartis) Clinical Trials, 2016
  • Table 9.3 Selected EPO Biosimilars Approved in India
  • Table 9.4 Biosimilar EPO Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 9.5 Biosimilar EPO Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 10.1 Selected Filgrastim Biosimilars Approved Worldwide
  • Table 10.2 Biosimilar G-CSF Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 10.3 Biosimilar G-CSF Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 11.1 Types of Interferon Used Therapeutically, 2016
  • Table 11.2 Approved Branded Interferon Therapies, 2016
  • Table 11.3 Biosimilar Interferons Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 11.4 Biosimilar Interferons Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 11.5 Selected Interferon Alfa Biosimilars Approved Worldwide, 2016
  • Table 11.6 Chronic Hepatitis B and C: Global Prevalence by Region, 2014
  • Table 11.7 Biosimilar Interferon Alfa Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 11.8 Biosimilar Interferon Alfa Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 11.9 Selected Interferon Beta Biosimilars Approved Worldwide
  • Table 11.10 Biosimilar Interferon Beta Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 11.11 Biosimilar Interferon Beta Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 12.1 Biosimilar Growth Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 12.2 Biosimilar Growth Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 12.3 Recent Bemfola / Afolia (Finox Biotech) Clinical Trials, 2016
  • Table 12.4 Biosimilar Fertility Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 12.5 Biosimilar Fertility Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 13.1 Expected Biologic Patent Expiries, 2016-2029
  • Table 13.2 Typical Models of Collaboration for Biosimilar Development
  • Table 13.2 Biosimilars product pipeline
  • Table 14.1 Biosimilars and Follow-On Biologics Market: Revenue ($bn) and Market Share (%) by Sector, 2016, 2020 and 2027
  • Table 14.2 Biosimilars and Follow-On Biologics Market: Revenue ($bn) and Market Share (%) by Region, 2016, 2020 and 2027

List of Figures

  • Figure 1.1 Main Segments and Sub-Segments of the Biosimilars Market, 2016
  • Figure 3.1 Biosimilars Market as Share of the Overall Biologics Market: Revenue ($bn), Market Share (%), 2016
  • Figure 3.2 Global Biosimilars Market Forecast: Revenue ($bn), 2014-2027
  • Figure 3.3 Drivers and Restraints for the Biosimilars Market, 2016
  • Figure 3.4 Global Biosimilars Market Forecasts by Submarket: Revenue ($bn), 2014-2027
  • Figure 3.5 Composition of the Biosimilars Market in 2016: Market Shares (%)
  • Figure 3.6 Composition of the Biosimilars Market in 2020: Market Shares (%)
  • Figure 3.7 Composition of the Biosimilars Market in 2027: Market Shares (%)
  • Figure 4.1 Regional Composition of the Biosimilars Market in 2016: Market Shares (%)
  • Figure 4.2 Global Biosimilars Market Forecast Segmented by Region: Revenue ($bn), 2014-2027
  • Figure 4.3 Market Shares (%) for the Major Regional Markets, 2014-2027
  • Figure 4.4 Regional Composition of the Biosimilars Market in 2020: Market Shares (%)
  • Figure 4.5 Regional Composition of the Biosimilars Market in 2027: Market Shares (%)
  • Figure 4.6 US Biosimilars Market Forecast: Revenue ($bn), 2014-2027
  • Figure 4.7 European Biosimilars Market Breakdown: Revenue ($bn), 2014
  • Figure 4.8 European Biosimilars Market Breakdown: Revenue ($bn), 2020
  • Figure 4.9 European Biosimilars Market Breakdown: Revenue ($bn), 2027
  • Figure 4.10 European Biosimilars Market Segmented by Leading Nations: Revenue ($bn), 2014-2027
  • Figure 4.11 German Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 4.12 French Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 4.13 UK Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 4.14 Italian Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 4.15 Spanish Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 4.16 Japanese Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 5.1 Leading Emerging Nations Biosimilar Market Shares: Revenues ($bn), 2014
  • Figure 5.2 Leading Emerging Nations Biosimilar Market Shares: Revenues ($bn), 2020
  • Figure 5.3 Leading Emerging Nations Biosimilar Market Shares: Revenues ($bn), 2027
  • Figure 5.4 Leading Emerging Nations Biosimilar Market Shares: Revenues ($bn), 2014-2027
  • Figure 5.5 Chinese Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 5.6 Indian Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 5.7 South Korean Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 5.8 Russian Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 5.9 Brazilian Biosimilars Market: Revenue ($bn), 2014-2027
  • Figure 6.1 Monoclonal Antibodies as a Percentage of the Total Biologics Market: Revenue ($bn), Market Share (%), 2016
  • Figure 6.2 The Best-Selling mAbs of 2016 as a Percentage of the Total Biologics Market: Revenue ($bn), Market Share (%), 2016
  • Figure 6.3 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), 2014-2027
  • Figure 6.4 Biosimilar Monoclonal Antibody Market Forecast, Split by Product: Revenue ($bn),2014-2027
  • Figure 6.5 Biosimilar Rituximab Revenue Forecast: Revenue ($bn), 2014-2027
  • Figure 6.6 Biosimilar Infliximab Revenue Forecast: Revenue ($bn), 2014-2027
  • Figure 6.7 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), 2014-2027
  • Figure 6.8 Biosimilar Adalimumab Revenue Forecast: Revenue ($bn), 2014-2027
  • Figure 6.9 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), 2014-2027
  • Figure 7.1 Fusion Proteins as a Percentage of the Total Biologics Market: Revenue ($m), Market Share (%), 2016
  • Figure 7.2 Biosimilar Fusion Proteins Market Forecast: Revenue ($bn), 2014-2027
  • Figure 7.3 Biosimilar Etanercept Market Forecast: Revenue ($bn), 2014-2027
  • Figure 8.1 Diabetes Prevalence in Leading National Markets, 2012
  • Figure 8.2 Biosimilar Insulin Market Forecast: Revenue ($bn), 2014-2027
  • Figure 8.3 Biosimilar Insulin Submarket Forecasts: Revenues ($bn), 2014-2027
  • Figure 8.4 Drivers and Restraints for the Biosimilar Insulin Market, 2016
  • Figure 8.5 Biosimilar Human Insulin Submarket Revenue Forecast: Revenue ($bn), 2014-2027
  • Figure 8.6 Biosimilar Insulin Analogues Submarket Forecast: Revenue ($bn), 2014-2027
  • Figure 8.7 Biosimilar Insulin Glargine Revenue Forecast: Revenue ($bn), 2014-2027
  • Figure 8.8 Biosimilar Insulin Lispro Revenue Forecast: Revenue ($bn), 2014-2027
  • Figure 9.1 Biosimilar EPO Market Forecast: Revenue ($bn), 2014-2027
  • Figure 10.1 Biosimilar G-CSF Market Forecast: Revenue ($bn), 2014-2027
  • Figure 11.1 Biosimilar Interferons Market Forecast: Revenue ($bn), 2014-2027
  • Figure 11.2 Chronic Hepatitis B: Global Prevalence Share (%) by Region, 2014
  • Figure 11.3 Chronic Hepatitis C: Global Prevalence Share (%) by Region, 2014
  • Figure 11.4 Biosimilar Interferon Alfa Market Forecast: Revenue ($bn), 2014-2027
  • Figure 11.5 Biosimilar Interferon Beta Market Forecast: Revenue ($bn), 2014-2027
  • Figure 12.1 Biosimilar Growth Hormone Market Forecast: Revenue ($bn), 2014-2027
  • Figure 12.2 Biosimilar Fertility Hormone Market Forecast: Revenue ($bn), 2014-2027
  • Figure 13.1 Strengths and Weaknesses of the Biosimilars Market, 2016-2027
  • Figure 13.2 Opportunities and Threats for the Biosimilars Market, 2016-2027
  • Figure 13.3 Biosimilar Development Costs by Stage, 2016
  • Figure 13.4 Typical Biosimilar Development Timeline
  • Figure 14.1 Biosimilars and Follow-On Biologics Market: Revenue ($bn), by Sector, 2016, 2020 and 2027
  • Figure 14.2 Biosimilars and Follow-On Biologics Market: Revenue ($bn), by Region, 2016, 2020 and 2027

Companies Listed

  • Allergan
  • Allozyne
  • Alteogen
  • Alvogen
  • Amarey Novamedical
  • Amega Biotech
  • Amgen
  • Apotex
  • Astellas Pharma
  • AstraZeneca
  • Avesthagen
  • Baxter
  • Bayer
  • Beijing Four Rings
  • Beijing SL Pharmaceutical
  • Biocad
  • Bioceuticals
  • Biogen
  • BioGenomics
  • Biolab
  • Bionovis
  • BioPartners
  • Biosidus
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cambridge Antibody Technology
  • CCL Pharmaceuticals
  • CCM Duopharma
  • Celltrion
  • Centocor Ortho Biotech
  • Chong Kun Dang
  • Chugai
  • CinnaGen.
  • Coherus BioSciences
  • Compass Biotechnologies
  • Cristália
  • CT Arzneimittel
  • Cyplasin
  • Daiichi Sankyo
  • Dong-A Pharmaceutical
  • Dr. Reddy's Laboratories
  • Egis Pharmaceuticals
  • Eisai
  • Eli Lilly
  • Elpen Pharmaceutical
  • Emcure Pharmaceuticals
  • EMS
  • Epirus
  • Eurofarma
  • Express Scripts
  • FibroGen
  • Finox Biotech
  • Fuji Pharma
  • Gan & Lee
  • Genetech
  • Genexine
  • Gennova
  • GenSci
  • Genzyme
  • Geropharm
  • Gilead Sciences
  • GlaxoSmithKline
  • Hangzhou Jiuyuan Gene Engineering Co.
  • Hanmi Pharmaceutical
  • Hanwha Chemical
  • Haselmeier
  • Health Canada
  • Helius Biotech
  • Hexal
  • Hindustan Antibiotic
  • Hospira
  • Hualida Biotech
  • Hypermarcas
  • IGES Institute
  • Intas Biopharmaceuticals
  • inVentiv Health
  • JCR Pharmaceuticals
  • Johnson & Johnson
  • Kabi
  • Kemwell Biopharma
  • Kissea
  • Koçak Farma
  • Kwizda Pharma
  • Kyowa Hakko Kirin
  • Landsteiner Scientific
  • LG Life Sciences
  • Libbs
  • LKM SA
  • Lonza
  • Mabion
  • Marvel Life Sciences
  • MEDICE Arzneimittel Pütter
  • Merck (MSD)
  • Merck KGaA
  • Merck Serono
  • Minapharm
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Momenta Pharmaceuticals
  • Mycenax Biotech
  • Mylan
  • Nichi-Iko
  • Nippion Kayaku
  • Novartis
  • Novo Nordisk
  • Nuron Biotech
  • Oncobiologics
  • Ortho Pharmaceutical
  • Orygen
  • PanGen Biotech
  • Pfenex
  • Pfizer
  • Pharmapark
  • Pharmstandard
  • PRA International
  • Pro Generika
  • PROBIOMED
  • Qilu Pharmaceutical
  • Quintiles
  • Ranbaxy Laboratories
  • RAND Corporation
  • Ratiopharm
  • Regeneron Pharmaceuticals
  • Reliance GeneMedix
  • Reliance Life Sciences (RLS)
  • Rentschler Biotechnologie
  • Roche
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • SciGen
  • Shandong Kexing Pharma
  • Shanghai Celgen Biopharmaceutical
  • Shanghai CP Guojian
  • Shanghai Fosun
  • Shantha Biotechnics
  • Shinogi
  • Sicor Biotech
  • Sothema Laboratories
  • Spectrum Pharmaceuticals
  • STADA Arzneimittel
  • Stragen Pharma
  • Strides Arcolab
  • Syngene International
  • Synthon Biopharmaceuticals
  • Takeda
  • Teva
  • Tianjin Hualida Biotechnology
  • Tonghua Dongbao
  • TSH Biopharm Corp
  • União Química
  • USV Biologics
  • Virchow Biotech
  • Wanbang Biopharmaceuticals
  • Wockhardt
  • Xiamen Amoytop Biotech
  • Zenotech
  • Zhejian Huahai Pharmaceutical
  • Zuventus
  • Zydus Biovation
  • Zydus Cadila

Organizations Mentioned in the Report

  • Argentine Ministry of Health
  • Cardiovascular and Renal Drugs Advisory Committee
  • Cardiovascular Drugs Advisory Committee
  • Centers of Medicare and Medicaid Services (CMS)
  • Central Drugs Standard Control Organisation
  • Centre for Drug Evaluation (CDE)
  • China Food and Drug Administration
  • Comisión Federal para la Protección contra Riesgos Sanitarios
  • Committee for Medicinal Products for Human Use
  • European Generic Medicines Association (EGA)
  • European Medicines Agency (EMA)
  • Intellectual Property Appellate Board (IPAB)
  • Korea Food and Drug Administration
  • Mexican Supreme Court
  • Ministry for Health Labour and Welfare (MHLW)
  • National Health Service (NHS)
  • National Institute for Health and Care Excellence (NICE)
  • Norwegian Ministry of Health
  • Pan American Health Organization
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • Russian Ministry of Health
  • Scottish Medicines Consortium (SMC)
  • Stanford University
  • State Employees' Social Security and Social Services Institute (ISSSTE)
  • The Brazilian Ministry of Health
  • The Drug Regulatory Authority of Pakistan
  • The Ministry of Food and Drug Safety (MFDS)
  • The National Conference of State Legislatures (US)
  • The United Laboratories (TUL)
  • Therapeutic Goods Administration
  • Toronto University
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • University of California, San Francisco
  • University of Tokyo
  • US Center for Disease Prevention and Control (CDC)
  • US Court of Appeals
  • US Food and Drug Administration (FDA)
  • US Patent and Trademark Office
  • World Health Organization (WHO)
Back to Top